4 results match your criteria: "The James Cancer Center at The Ohio State University[Affiliation]"
Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial.
JAMA Oncol
March 2024
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Importance: The potential benefit of combining intracranial effective systemic therapy with radiotherapy for patients with breast cancer with brain metastases remains unclear.
Objective: To assess the activity and safety of combining radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive breast cancer and brain metastases.
Design, Setting, And Participants: This was a single-arm, single-center, phase 2 nonrandomized clinical trial with a safety run-in phase.
Feasibility, safety, and efficacy of circumferential spine stereotactic body radiotherapy.
Front Oncol
November 2022
Department of Radiation Oncology, The James Cancer Center at the Ohio State University Wexner Medical Center, Columbus, OH, United States.
Background: With advances in systemic therapy translating to improved survival in metastatic malignancies, spine metastases have become an increasingly common source of morbidity. Achieving durable local control (LC) for patients with circumferential epidural disease can be particularly challenging. Circumferential stereotactic body radiotherapy (SBRT) may offer improved LC for circumferential vertebral and/or epidural metastatic spinal disease, but prospective (and retrospective) data are extremely limited.
View Article and Find Full Text PDFAssociation of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial.
JAMA Oncol
December 2022
CHUM, Montreal, Quebec, Canada.
Importance: Long-term outcomes of radiotherapy are important in understanding the risks and benefits of therapies for patients with brain metastases.
Objective: To determine how the use of postoperative whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) is associated with quality of life (QOL), cognitive function, and intracranial tumor control in long-term survivors with 1 to 4 brain metastases.
Design, Setting, And Participants: This secondary analysis of a randomized phase 3 clinical trial included 48 institutions in the US and Canada.
Preface.
Chin Clin Oncol
August 2017
Assistant Professor, Division of Pediatric and Central Nervous System Tumors, The James Cancer Center at The Ohio State University, Columbus, OH, USA.